Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 4. (A) Venn diagram showing the overlap of peaks differentially changed in DHT as compared to NT with peaks ... Figure 4. (A) Venn diagram showing.

Published byLeopold Aalderink Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 4. (A) Venn diagram showing the overlap of peaks differentially changed in DHT as compared to NT with peaks ... Figure 4. (A) Venn diagram showing."— Presentation transcript:

1 Figure 4. (A) Venn diagram showing the overlap of peaks differentially changed in DHT as compared to NT with peaks ... Figure 4. (A) Venn diagram showing the overlap of peaks differentially changed in DHT as compared to NT with peaks changed by DHT and ARE-1 as compared to NT. (B and C) Density analysis of overlapping peaks with <1.5 absolute fold change between DHT/NT and DHT+ARE-1/NT (B) and peaks with >2-fold change when comparing DHT/NT to DHT+ARE-1/NT (C). Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of Nucleic Acids Research.This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Nucleic Acids Res, gkz153, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Figure 3. (A) Illustration of match and mismatch ARE-1 binding sites
Figure 3. (A) Illustration of match and mismatch ARE-1 binding sites. Mismatches are shown in red and boxed. (B) ... Figure 3. (A) Illustration of match and mismatch ARE-1 binding sites. Mismatches are shown in red and boxed. (B) Melting temperature analysis of match and mismatch sequences shown in A. C + D) Motif density analysis of possible ARE half sites in peaks unique to DHT/NT (C) and overlapping between DHT/NT and DHT/DHT + ARE-1 (D). Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of Nucleic Acids Research.This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Nucleic Acids Res, gkz153, The content of this slide may be subject to copyright: please see the slide notes for details.

3 Figure 2. ChIP-seq analysis of the KLK3 promoter ARE I (A) and PMEPA1 (B). (C) Overlap of peaks differentially changed ... Figure 2. ChIP-seq analysis of the KLK3 promoter ARE I (A) and PMEPA1 (B). (C) Overlap of peaks differentially changed in DHT relative to NT, and peaks changed in DHT relative to DHT and ARE-1. (D) Identified peaks were annotated by genomic region by ChIPseeker. (E) Top ARE motif found by MEME in the indicated peak sets. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of Nucleic Acids Research.This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Nucleic Acids Res, gkz153, The content of this slide may be subject to copyright: please see the slide notes for details.

4 Figure 1. (A) Structure of Py-Im polyamide ARE-1
Figure 1. (A) Structure of Py-Im polyamide ARE-1. (B) Nuclear localization of ARE-1-FITC in LNCaP-95 cells after 16-h ... Figure 1. (A) Structure of Py-Im polyamide ARE-1. (B) Nuclear localization of ARE-1-FITC in LNCaP-95 cells after 16-h treatment. (C) Cell viability as determined by CellTiterGlo assay after 72-h treatment. IC<sub>50</sub> is indicated in parentheses. (D) Relative expression of KLK3 in LNCaP-95 cells after the indicated treatments. Cells were co-treated with ARE-1, enzalutamide, or pyrvinium pamoate and DHT at the indicated concentrations and RNA harvested at 24 h. (E) Schedule of LNCaP-95 xenograft experiment. Animals were engrafted, allowed to grow tumors, castrated, allowed to recover for 7–10 days and then treated with ARE-1 or vehicle at indicated times. (F) Tumor volumes of LNCaP-95 xenografts in castrated mice treated with vehicle or 2.5 mg/kg ARE-1 as shown in E. N = 11 for both groups; * P < 0.05, ** P < 0.01, **** P < Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of Nucleic Acids Research.This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Nucleic Acids Res, gkz153, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 4. (A) Venn diagram showing the overlap of peaks differentially changed in DHT as compared to NT with peaks ... Figure 4. (A) Venn diagram showing."

Similar presentations

Figure 2. The graphic integration of CNAs with altered expression genes in lung AD and SCC. The red lines represent the amplification regions for CNA and.

Figure 2. The graphic integration of CNAs with altered expression genes in lung AD and SCC. The red lines represent the amplification regions for CNA and.
From: Introducing the PRIDE Archive RESTful web services

From: Introducing the PRIDE Archive RESTful web services
Figure 1. (A) The VEGF promoter PQS and scheme of G oxidation to OG, as well as (B) the proposed APE1-dependent pathway ... Figure 1. (A) The VEGF promoter.

Figure 1. (A) The VEGF promoter PQS and scheme of G oxidation to OG, as well as (B) the proposed APE1-dependent pathway ... Figure 1. (A) The VEGF promoter.
Figure 1. Circular taxonomy tree based on the species that were sequenced in our study. Unless provided in the caption above, the following copyright applies.

Figure 1. Circular taxonomy tree based on the species that were sequenced in our study. Unless provided in the caption above, the following copyright applies.
Figure 1. A novel image analysis tool to monitor epigenetic changes in spatiotemporal distribution of chromatin in live ... Figure 1. A novel image analysis.

Figure 1. A novel image analysis tool to monitor epigenetic changes in spatiotemporal distribution of chromatin in live ... Figure 1. A novel image analysis.
Figure 1. Overview of the workflow of NetworkAnalyst 3.0.

Figure 1. Overview of the workflow of NetworkAnalyst 3.0.
Figure 1 The study area within Vienna Zoo is outlined in red

Figure 1 The study area within Vienna Zoo is outlined in red
Figure 7. Primary cells from prostate tumours are more sensitive to ML-60218 than adjacent non-cancerous cells from the ... Figure 7. Primary cells from.

Figure 7. Primary cells from prostate tumours are more sensitive to ML than adjacent non-cancerous cells from the ... Figure 7. Primary cells from.
Figure 1. AML containing the t(8:21) are extremely sensitive to CDK inhibitors. (A–C) Alamar blue assays were used to ... Figure 1. AML containing the.

Figure 1. AML containing the t(8:21) are extremely sensitive to CDK inhibitors. (A–C) Alamar blue assays were used to ... Figure 1. AML containing the.
Figure 1. Effect of random T/A→dU/A substitutions on transcription by T7 RNAP using a 321 bp DNA transcription template ... Figure 1. Effect of random.

Figure 1. Effect of random T/A→dU/A substitutions on transcription by T7 RNAP using a 321 bp DNA transcription template ... Figure 1. Effect of random.
FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.

FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.
Figure 1. Position and number of NLS improves genome editing by AsCas12a, LbCas12a and FnoCas12a. (A) General schematic ... Figure 1. Position and number.

Figure 1. Position and number of NLS improves genome editing by AsCas12a, LbCas12a and FnoCas12a. (A) General schematic ... Figure 1. Position and number.
FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels

FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels
Figure 2. Ectopic expression of PLZF modulates H3K27ac at enhancer regions in myeloid cells. (A) Box plots showing ... Figure 2. Ectopic expression of.

Figure 2. Ectopic expression of PLZF modulates H3K27ac at enhancer regions in myeloid cells. (A) Box plots showing ... Figure 2. Ectopic expression of.
Figure 1. BRCA1-associated R-Loop accumulation at a non-coding region upstream of ESR1 locus. (A) Alignment of DRIP-seq ... Figure 1. BRCA1-associated.

Figure 1. BRCA1-associated R-Loop accumulation at a non-coding region upstream of ESR1 locus. (A) Alignment of DRIP-seq ... Figure 1. BRCA1-associated.
FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:

FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:
Figure 1. Designing a cell-specific Cas-ON switch based on miRNA-regulated anti-CRISPR genes. (A) Schematic of the ... Figure 1. Designing a cell-specific.

Figure 1. Designing a cell-specific Cas-ON switch based on miRNA-regulated anti-CRISPR genes. (A) Schematic of the ... Figure 1. Designing a cell-specific.
FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.

FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.
Figure 1. Schematic illustration of CSN and NDM construction and our statistic model. (A) CSN and NDM construction. (i) ... Figure 1. Schematic illustration.

Figure 1. Schematic illustration of CSN and NDM construction and our statistic model. (A) CSN and NDM construction. (i) ... Figure 1. Schematic illustration.
Figure 1. Ratios of observed to expected numbers of exon boundaries aligning to boundaries of domain and disorder ... Figure 1. Ratios of observed to expected.

Figure 1. Ratios of observed to expected numbers of exon boundaries aligning to boundaries of domain and disorder ... Figure 1. Ratios of observed to expected.

Similar presentations

Ads by Google